Sequence Bio is researching the founder population in Newfoundland and Labrador to identify novel genetic causes of diseases with global unmet medical needs.
Sequence Bio is based in Newfoundland and Labrador, and proudly collaborates with the people and medical professionals of the province, and leading research organizations, to help accelerate the discovery and development of better preventions, treatments, and medicines.
Familial Ovarian Cancer
The Study of Familial Ovarian Cancer focuses on families in Newfoundland and Labrador to identify and understand how inherited genetic factors contribute to the development of ovarian cancer.
Insights from the Study of Familial Ovarian Cancer may help improve diagnosis and advance global drug discovery and development programs.
Familial Multiple Sclerosis
The Study of Familial Multiple Sclerosis is focused on identifying and determining if genetic factors in Newfoundland and Labrador families contribute to the development of multiple sclerosis.
Insights from the Study of Familial Multiple Sclerosis may help improve diagnosis and advance global drug discovery and development programs.
NL Genome Project
The NL Genome Project is a general population genomics study focused on characterizing the founder effect and genetic architecture of the Newfoundland and Labrador population.
Insights from the NL Genome Project help inform the design and development of additional Sequence Bio studies for the discovery and validation of therapeutic targets in select disease areas.
Sequence Bio is conducting research in Newfoundland and Labrador, and doing so in an ethical way is our first priority. Our research efforts require approval by the Health Research Ethics Board (HREB), and the words “believe,” “expect,” “anticipate,” and similar expressions, among others, generally identify our intent and/or objective to undertake additional research in this province.
